Overview of the ASX Healthcare Market in 2026
In 2026, two of the largest healthcare stocks listed on the Australian Securities Exchange (ASX) have experienced significant declines. Pro Medicus Ltd (ASX: PME) has seen its value drop by 38% year to date, while Cochlear Ltd (ASX: COH) has fallen by an even steeper 63%. These substantial losses have contributed significantly to the overall decline of the S&P/ASX 200 Health Care Index (ASX: XHJ), which has also dropped by 22% during the same period.
The sharp downturn has prompted many analysts and brokers to reassess their outlooks on these companies, leading to a mix of cautious optimism and concern about future performance.
Pro Medicus: A Company with Strong Fundamentals
Pro Medicus is a global provider of medical imaging technology, known for its radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions. It is among the top five largest healthcare companies on the ASX by market capitalisation. Despite its strong position in the industry, the company has faced a brutal decline over the past year, falling nearly 60% from its 12-month high of $330 in July 2025, with shares closing at $138.12 as of yesterday.
Analysts believe that the current valuation of Pro Medicus may be undervalued. Medallion Financial Group recently highlighted that recent contract renewals with higher fees and the share price weakness could act as tailwinds for the company. Morgans has maintained its “buy” rating on Pro Medicus, setting a price target of $210.00, which suggests a potential upside of 52% from the current price.
The broker’s confidence stems from “exceptional” contract newsflow since February, reinforcing long-term positive convictions, despite acknowledging some short-term headwinds.
Cochlear: A Leading Player Facing Challenges
Cochlear, the world’s leading manufacturer of cochlear implants, holds approximately half of the global market share. However, the company’s stock has suffered a major setback, with a 2.5% decline yesterday, bringing its year-to-date loss to 63%. The bulk of this drop occurred last week after the company revised its earnings outlook, causing a dramatic 40% single-day decline in its share price.
Despite this, sentiment regarding Cochlear remains mixed. As of yesterday, the stock closed at $95.25. Analysts have provided varied price targets:
- Jarden has set a target of $169.
- Macquarie has reduced its 12-month target to $115 from $239.
- Morgans has a hold rating with a target of $107.17.
These differing opinions highlight the uncertainty surrounding the company’s future performance.
Long-Term Potential and Short-Term Volatility
When traditional blue-chip stocks experience significant declines, it often draws considerable attention from investors. While there is potential for recovery in the long term, several challenges need to be addressed before this can happen. Investors looking to buy low on these options should be prepared for increased volatility in the short term.
Key Takeaways for Investors
Both Pro Medicus and Cochlear are facing difficult market conditions, but each has unique strengths and challenges. Pro Medicus appears to have more analyst support and a clearer path to recovery, while Cochlear’s future remains uncertain due to recent earnings concerns.
For those considering investment opportunities, it is essential to evaluate the broader market trends and the specific fundamentals of each company. With careful analysis and a long-term perspective, these beaten-down healthcare stocks could present compelling opportunities for growth.
Additional Resources
Investors interested in further insights into the ASX healthcare sector may want to explore additional analyses and recommendations from financial experts. These resources can provide a deeper understanding of market dynamics and help inform investment decisions.
